Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01529034 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Long-term Safety and Tolerability of USL261 in Patients With Seizure Clusters
A Phase 3 study, sponsored by UCB Biopharma S.P.R.L..
- Terminated
- Registry status
- Phase 3
- Development phase
- 175
- Enrollment target
NCT01529034 is a Phase 3 study that was terminated before completion, run by UCB Biopharma S.P.R.L.. The registered enrollment target is 175 participants.
The verdict
NCT01529034, a Phase 3 study, was terminated before completion, sponsored by UCB Biopharma S.P.R.L..
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 175 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the long-term safety and tolerability of USL261 in the treatment of seizure clusters.
Interventions
- DRUG USL261
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 175 participants |
| Start Date | 2012-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01529034
The ClinicalTrials.gov registry entry for NCT01529034 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 175 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biopharma S.P.R.L., which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which USL261 is the first listed.
NCT01529034 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01529034 about?
NCT01529034 is a clinical study titled "Study to Evaluate the Long-term Safety and Tolerability of USL261 in Patients With Seizure Clusters". The purpose of this study is to examine the long-term safety and tolerability of USL261 in the treatment of seizure clusters.
What is the current status of trial NCT01529034?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 175 participants. The study started on 2012-07.
What interventions are being tested in trial NCT01529034?
The interventions under investigation include: USL261 (DRUG).
Who is sponsoring clinical trial NCT01529034?
This trial is sponsored by UCB Biopharma S.P.R.L., which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.